However, up to 64.3% of them had converted into secondary progressive multiple sclerosis during Phase 1, and only 20.3% of those who had relapses during Phase 2 (P < 0.0001).
With respect to human populations, the use of anti-LINGO-1 as a method of medical treatment for multiple sclerosis (MS) cleared phase I clinical trials in April 2012 and has since moved into phase II [ 181– 181].
Fingolimod has recently been approved as an oral treatment option for multiple sclerosis, and two phase III clinical studies demonstrated a significant reduction in the relapse rate in patients with relapsing-remitting multiple sclerosis compared with interferon and placebo.
This prompted us to define two phases in the multiple sclerosis disease course, an early phase and a late phase.
We aimed to assess the safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis in a combined phase 1, 2, and 3 clinical trial.
To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS) in the phase 3 ADVANCE study (n = 1512).
Consistently, in relapsing onset multiple sclerosis, the duration of Phase 1 was shorter in males than in females (9.0 versus 10.0 years, P < 0.005), while the duration of Phase 2 was similar in both genders (7.0 versus 7.7 years, P = 0.371).
Multiple Sclerosis has two clinical phases reflecting distinct but inter-related pathological processes: focal inflammation drives the relapse-remitting stage and neurodegeneration represents the principal substrate of secondary progression.
In the majority of patients multiple sclerosis has two clinical phases reflecting distinct but inter-related pathological processes: focal inflammation drives activity during the relapse-remitting (RR) stage and neuroaxonal degeneration represents the principal substrate of secondary progression (SP), a stage that has few if any relapses.
In relapsing onset multiple sclerosis, the disability progression during Phase 1 was much slower, and that during Phase 2 was somehow slower, than in progressive onset multiple sclerosis.
